Babaie Delara, Shamsian Bibi Shahin, Momtazmanesh Nader, Godarzipour Hamidreza, Amirmoini Mehrdad, Bashardoust Bahram, Ebrahimi Masoomeh, Vahedi Mahdieh, Ghaemi Reza, Mesdaghi Mehrnaz
Department of Immunology and Allergy, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pediatric Congenital Hematologic Disorders Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2019 Spring;18(2):1047-1051. doi: 10.22037/ijpr.1999.1100664.
Usage of cancer chemotherapeutics drugs can be associated with adverse drug reactions. When IgE-mediated drug reactions are formed following administration of a chemotherapeutics drug that is a drug of choice, drug desensitization protocols can be helpful. HSR can be allergic or nonallergic, but the clinical manifestations are similar. RDD is effective when used appropriately, however it is often over utilized instead of performing a drug challenge. RDD is both an acceptable approach and a high-risk treatment modality in patients, in whom the offending agent is the first choice in chemotherapy. The safety of this modality has been acceptable in large studies. The side effects are often less frequent and less severe by repeating the protocol. We present 4 cases of successful desensitization in cancer patients, who have developed IgE- mediated reactions to their major chemotherapy drug.
癌症化疗药物的使用可能与药物不良反应相关。当使用首选化疗药物后形成IgE介导的药物反应时，药物脱敏方案可能会有所帮助。速发型超敏反应（HSR）可以是过敏性的或非过敏性的，但临床表现相似。合理使用时，反应性药物停药（RDD）是有效的，然而它常常被过度使用，而不是进行药物激发试验。在那些致病药物是化疗首选药物的患者中，RDD既是一种可接受的方法，也是一种高风险的治疗方式。在大型研究中，这种治疗方式的安全性是可以接受的。通过重复该方案，副作用往往频率更低、程度更轻。我们报告了4例癌症患者成功脱敏的病例，这些患者对其主要化疗药物发生了IgE介导的反应。
